Negative association between serum levels of matrix metalloproteinases-2 and -9 and aortic stiffness in healthy adults

International Journal of Cardiology

Volumn 122, Issue 3, 2007, Pages 232-238

  Vlachopoulos, Charalambos ^a   Aznaouridis, Konstantinos ^a   Dima, Ioanna ^a   Ioakeimidis, Nikolaos ^a   Vasiliadou, Carmen ^a   Zervoudaki, Alexandra ^a   Gialernios, Theodoros ^a   Stefanadis, Christodoulos ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Arterial stiffness; Extracellular matrix; Gelatinase; Matrix metalloproteinase; Wave reflections

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GELATINASE A; GELATINASE B; GLUCOSE;

ADULT; AORTA DISEASE; AORTA STIFFNESS; ARTICLE; BLOOD PRESSURE; BODY MASS; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; EXTRACELLULAR MATRIX; FEMALE; FEMORAL ARTERY; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; INFLAMMATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SMOKING HABIT;

ADOLESCENT; ADULT; AORTA; AORTIC DISEASES; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED;

EID: 34250751597     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.099     Document Type: Article

References (43)

1. Jacob M.P. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed Pharmacother 57 (2003) 195-202
2. Schiffrin E.L. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 17 (2004) 1192-1200
3. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix meatalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
4. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., and Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 110 (2002) 625-632
5. Pla-Rodriguez A., Bosch-Gil J.A., Rossello-Urgell J., Huguet-Redecilla P., Stone J.H., and Vilardell-Tarres M. Metalloproteinase-2 and -9 in giant cell arteritis. Involvement in vascular remodeling. Circulation 112 (2005) 264-269
6. London G.M., Blacher J., Pannier B., Guerin A.P., Marchais S.J., and Safar M. Arterial wave reflections and survival in end-stage renal failure. Hypertension 38 (2001) 434-438
7. Stefanadis C., Dernellis J., Tsiamis E., et al. Aortic stiffness is a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. Eur Heart J 21 (2000) 390-396
8. Blacher J., Asmar R., Djane S., London G.M., and Safar M.E. Aortic pulse velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 33 (1999) 1111-1117
9. Laurent S., Boutouyrie P., Asmar R., et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37 (2001) 1236-1241
10. Nichols WW, O'Rourke MF, editors. McDonald's blood flow in arteries. 4th ed. London: Edward Arnold;1998, pp. 170-222, 284-315, 347-395, 450-476.
11. Willum-Hansen T., Staessen J.A., Torp-Pedersen C., et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 113 (2006) 664-670
12. Visse R., and Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, function, and biochemistry. Circ Res 92 (2003) 827-839
13. Yasmin, Wallace S., McEniery C.M., et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25 (2005) 372-378
14. Medley T.L., Cole T.J., Dart A.M., Gatzka C.D., and Kinqwell B.A. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 24 (2004) 1479-1484
15. Liu P.Y., Tsai W.C., Lin C.C., Hsu C.H., Haung Y.Y., and Chen J.H. Invasive measurements of pulse wave velocity correlate with the degree of aortic valve calcification and severity associated with matrix metalloproteinases in elderly patients with aortic valve stenosis. Clin Sci 107 (2004) 415-422
16. Vlachopoulos C., Dima I., Aznaouridis K., et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 112 (2005) 2193-2200
17. O'Rourke M., Staessen J., Vlachopoulos C., Duprez D., and Plante G. Clinical applications of arterial stiffness; definitions and reference values. Am J Hypertens 15 (2002) 426-444
18. Vlachopoulos C., Hirata K., and O'Rourke M. Effect of caffeine of aortic function and wave reflection. J Hypertens 21 (2003) 563-570
19. Vlachopoulos C., Kosmopoulou F., Panagiotakos D., et al. Smoking and caffeine have a synergistic detrimental effect on aortic stiffness and wave reflections. J Am Coll Cardiol 44 (2004) 1911-1917
20. Asmar R., Benetos A., Topouchian J., et al. Assessment of arterial distensibility by automatic pulse wave velocity measurement: validation and clinical application studies. Hypertension 26 (1995) 485-490
21. Pauca A., O'Rourke M., and Kon N. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 38 (2001) 932-937
22. Vlachopoulos C., Hirata K., and O'Rourke M. Pressure-altering agents affect central aortic pressures more than is apparent from upper limb measurements in hypertensive patients: the role of arterial wave reflections. Hypertension 38 (2001) 1456-1460
23. Vlachopoulos C., and O'Rourke M. Genesis of the normal and abnormal arterial pulse. Curr Probl Cardiol 25 (2000) 297-368
24. Yasmin, McEniery C.M., Wallace S., Mackenzie I.S., Cockcroft J.R., and Wilkinson I.B. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 24 (2004) 969-974
25. Ergul A., Potrik-Dobos V., Hutchinson J., Franco J., and Anstadt M.P. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 17 (2004) 775-782
26. Zervoudaki A., Economou E., Stefanadis C., et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 17 (2003) 119-124
27. + channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 17 (2004) 273-276
28. Stefanadis C., Dernellis J., Vlachopoulos C., et al. Aortic function in arterial hypertension determined by pressure-diameter relation: effects of diltiazem. Circulation 101 (1997) 1819-1825
29. Keeley F.W., Elmoselhi A., and Leenen F.H. Effects of antihypertensive drug classes on regression of connective tissue components of hypertension. J Cardiovasc Pharmacol 17 Suppl 2 (1991) S64-S69
30. Michel J.B., Heudes D., Michel O., et al. Effect of chronic ANG-I converting enzyme inhibition on aging process. II. Large arteries. Am J Physiol 267 (1994) R124-R135
31. Wilson K.A., Lee A.J., Lee A.J., et al. The relationship between aortic wall distensibility and rupture of infrarenal abdominal aortic aneurysm. J Vasc Surg 37 (2003) 112-117
32. Brilla C.G., Rupp H., and Maisch B. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Herz 28 (2003) 744-753
33. Laviades C., Varo N., Fernandez J., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 98 (1998) 535-540
34. Wilkinson I.B., Franklin S.S., and Cockcroft J.R. Nitric oxide and the regulation of large artery stiffness. From physiology to pharmacology. Hypertension 44 (2004) 112-116
35. Tronc F., Mallat Z., Lehoux S., Wassef M., Esposito B., and Tedgui A. Role of matrix metalloproteinases in blood flow-induced arterial enlargement. Interaction with NO. Arterioscler Thromb Vasc Biol 20 (2000) e120-e126
36. Medley T.L., Kingwell B.A., Gatzka C.D., Pillay P., and Cole T.J. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 92 (2003) 1254-1261
37. Fernandez-Patron C., Stewart K.G., Zhang Y., Koivunen E., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87 (2000) 670-676
38. Bouvet C., Gilbert L.A., Girardot D., deBlois D., and Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45 (2005) 432-437
39. Tayebjee M.H., Nadar S., Blann A.D., Beevers D.G., Mac Fadyen R.J., and Lip G.Y.H. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment. A Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17 (2004) 764-769
40. Blankenberg S., Rupprecht H.J., Poirier O., et al., for the AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
41. Galis Z.S., Johnson C., Godin D., et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 91 (2002) 852-859
42. Ikejiri M., Bernardo M., Bonfil R.D., et al. Potent mechanism-based inhibitors for matrix metalloproteinases. J Biol Chem 280 (2005) 33992-34002
43. Tayebjee M.H., Lip G.Y.H., Blann A.D., and MacFadyen R.J. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and -2. Thromb Res 115 (2005) 105-210